The brachial plexus may also be compressed by surrounding damaged structures such as bone fragments or callus from the clavicular fracture, and hematoma or pseudoaneurysm from vascular injury. Cervical rib, prominent transverse process, and congenital fibrous bands can also compress the brachial plexus and cause thoracic outlet syndrome.During the delivery of a baby, the shoulder of the baby may graze against the pelvic bone of the mother. During this process, the brachial plexus can receive damage resulting in injury. The incidence of this happening at birth is 1 in 1000. This is very low compared to the other identified brachial plexus injuries. Diagnosis
The most accurate test for diagnosing a brachial plexus injury is operative exploration of the potentially injured segments from the spinal roots to end-organs. Nerves should be evaluated under an operative microscope, with or without intraoperative electrical studies (e.g. bipolar stimulation, SEPs or MEPs) to supplement. Operative evaluation of the rootlets within the spinal canal and intraforaminal portion of the spinal roots proximal to the dorsal root ganglia  (e.g. via hemilamiinectomy or otherwise) is difficult and rarely clinically justifiable, so in the context of an apparently in-continuity root, preoperative imaging studies are the only method of evaluating this section of nerve.The best non-invasive test for BPI is magnetic resonance imaging (MRI). MRI aids in the assessment of the injuries and is used to provide information on the portion of the plexus which cannot be operatively explored (the rootlets and roots).
Duration of action
Neuromuscular-blocking agents can be classified in accordance to their duration of pharmacological action, defined as follows:

Side effects
Cardiovascular
The tetrahydroisoquinolinium class of neuromuscular blocking agents, in general, is associated with histamine release upon rapid administration of a bolus intravenous injection. There are some exceptions to this rule; e.g., cisatracurium (Nimbex) is one such agent that does not elicit histamine release even up to 5xED95 doses. The liberation of histamine is a dose-dependent phenomenon such that, with increasing doses administered at the same rate, there is a greater propensity for eliciting histamine release and its ensuing sequelae. Most commonly, the histamine release following administration of these agents is associated with observable cutaneous flushing (facial face and arms, commonly), hypotension and a consequent reflex tachycardia. These sequelae are very transient effects: The total duration of the cardiovascular effects is no more than one to two minutes, while the facial flush may take around 3–4 minutes to dissipate. Because these effects are so transient, there is no reason to administer adjunctive therapy to ameliorate either the cutaneous or the cardiovascular effects. Bronchospasm
Bronchospasm has been reported on occasion with the use of atracurium. However, this particular undesirable effect does not appear to be observed nearly as often as that seen with rapacuronium, which led to the latters withdrawal of approval for clinical use worldwide.